Marco Vitolo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4883513/publications.pdf Version: 2024-02-01



ΜΑΡΟΟ ΥΙΤΟΙ Ο

#	Article	IF	CITATIONS
1	Optimizing indices of atrial fibrillation susceptibility and burden to evaluate atrial fibrillation severity, risk and outcomes. Cardiovascular Research, 2021, 117, 1-21.	1.8	67
2	The role of physical activity in individuals with cardiovascular risk factors: an opinion paper from Italian Society of Cardiology-Emilia Romagna-Marche and SIC-Sport. Journal of Cardiovascular Medicine, 2019, 20, 631-639.	0.6	43
3	Beyond the 2020 guidelines on atrial fibrillation of the European society of cardiology. European Journal of Internal Medicine, 2021, 86, 1-11.	1.0	40
4	Comparing Outcomes in Asymptomatic and Symptomatic Atrial Fibrillation: A Systematic Review and Meta-Analysis of 81,462 Patients. Journal of Clinical Medicine, 2021, 10, 3979.	1.0	34
5	Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients. European Heart Journal, 2021, 42, 3541-3554.	1.0	32
6	Device-detected atrial high rate episodes and the risk of stroke/thrombo-embolism and atrial fibrillation incidence: a systematic review and meta-analysis. European Journal of Internal Medicine, 2021, 92, 100-106.	1.0	31
7	Clinical Factors Associated with Atrial Fibrillation Detection on Single-Time Point Screening Using a Hand-Held Single-Lead ECG Device. Journal of Clinical Medicine, 2021, 10, 729.	1.0	30
8	What do we do about atrial high rate episodes?. European Heart Journal Supplements, 2020, 22, O42-O52.	0.0	29
9	Atrial fibrillation pattern and factors affecting the progression to permanent atrial fibrillation. Internal and Emergency Medicine, 2021, 16, 1131-1140.	1.0	27
10	Comparing atrial fibrillation guidelines: Focus on stroke prevention, bleeding risk assessment and oral anticoagulant recommendations. European Journal of Internal Medicine, 2022, 101, 1-7.	1.0	27
11	The Euro Heart Survey and EURObservational Research Programme (EORP) in atrial fibrillation registries: contribution to epidemiology, clinical management and therapy of atrial fibrillation patients over the last 20Âyears. Internal and Emergency Medicine, 2020, 15, 1183-1192.	1.0	25
12	Integrated care and outcomes in patients with atrial fibrillation and comorbidities. European Journal of Clinical Investigation, 2021, 51, e13498.	1.7	25
13	Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry. Clinical Research in Cardiology, 2022, 111, 70-84.	1.5	25
14	Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry. BMC Medicine, 2021, 19, 256.	2.3	22
15	Long-term outcomes of postoperative atrial fibrillation following non cardiac surgery: A systematic review and metanalysis. European Journal of Internal Medicine, 2021, 85, 27-33.	1.0	21
16	Mobile health technology in atrial fibrillation. Expert Review of Medical Devices, 2022, 19, 327-340.	1.4	19
17	Cardiolaminopathies from bench to bedside: challenges in clinical decision-making with focus on arrhythmia-related outcomes. Nucleus, 2018, 9, 442-459.	0.6	17
18	Atrial Fibrillation and the Risk of Earlyâ€Onset Dementia: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2022, 11, .	1.6	17

MARCO VITOLO

#	Article	IF	CITATIONS
19	Cognitive impairment in patients with atrial fibrillation: Implications for outcome in a cohort study. International Journal of Cardiology, 2021, 323, 83-89.	0.8	15
20	Clinical Phenotype Classification of Atrial Fibrillation Patients Using Cluster Analysis and Associations with Trial-Adjudicated Outcomes. Biomedicines, 2021, 9, 843.	1.4	15
21	Comparison of HAS-BLED and ORBIT bleeding risk scores in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants: a report from the ESC-EHRA EORP-AF General Long-Term Registry. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 778-786.	1.8	15
22	COVID-19 pandemic: complex interactions with the arrhythmic profile and the clinical course of patients with cardiovascular disease. European Heart Journal, 2021, 42, 529-532.	1.0	15
23	Rhythm- or rate-control strategies according to 4S-AF characterization scheme and long-term outcomes in atrial fibrillation patients: the FAMo (Fibrillazione Atriale in Modena) cohort. Internal and Emergency Medicine, 2022, 17, 1001-1012.	1.0	15
24	Cooling dynamics: a new predictor of long-term efficacy of atrioventricular nodal reentrant tachycardia cryoablation. Journal of Interventional Cardiac Electrophysiology, 2017, 48, 333-341.	0.6	14
25	Infections associated with cardiac electronic implantable devices: economic perspectives and impact of the TYRXâ,,¢ antibacterial envelope. Europace, 2021, 23, iv33-iv44.	0.7	14
26	Usefulness of Red Cells Distribution Width to Predict Worse Outcomes in Patients With Atrial Fibrillation. American Journal of Cardiology, 2019, 124, 1561-1567.	0.7	13
27	Epidemiology of subclinical atrial fibrillation in patients with cardiac implantable electronic devices: A systematic review and meta-regression. European Journal of Internal Medicine, 2022, 103, 84-94.	1.0	13
28	Red Cell Distribution Width: A Routinely Available Biomarker with Important Clinical Implications in Patients with Atrial Fibrillation. Current Pharmaceutical Design, 2021, 27, 3901-3912.	0.9	12
29	Atrial fibrillation in patients with cardiac implantable electronic devices: new perspectives with important clinical implications. Kardiologia Polska, 2019, 77, 1119-1120.	0.3	12
30	Implantable cardioverter defibrillators and devices for cardiac resynchronization therapy: what perspective for patients' apps combined with remote monitoring?. Expert Review of Medical Devices, 2022, 19, 155-160.	1.4	12
31	Atrial cardiomyopathy: a derangement in atrial volumes, geometry, function, and pathology with important clinical implications. Journal of Cardiovascular Medicine, 2022, 23, 359-362.	0.6	12
32	Percutaneous pericardiocentesis for pericardial effusion: predictors of mortality and outcomes. Internal and Emergency Medicine, 2021, 16, 1771-1777.	1.0	11
33	Performance-based risk-sharing arrangements for devices and procedures in cardiac electrophysiology: an innovative perspective. Europace, 2022, 24, 1541-1547.	0.7	11
34	Managing atrial fibrillation: the need for an individualized approach even in the emergency department. Internal and Emergency Medicine, 2020, 15, 9-12.	1.0	10
35	Atrial fibrillation and remote monitoring through cardiac implantable electronic devices in heart failure patients. European Journal of Heart Failure, 2020, 22, 554-556.	2.9	10
36	Understanding the global burden of atrial fibrillation and regional variations: we need improvement. Cardiovascular Research, 2021, 117, 1420-1422.	1.8	10

MARCO VITOLO

#	Article	IF	CITATIONS
37	Radiotherapy-induced malfunctions of cardiac implantable electronic devices in cancer patients. Internal and Emergency Medicine, 2020, 15, 967-973.	1.0	9
38	Red Cell Distribution Width and Patient Outcome in Cardiovascular Disease: A â€~'Real-World'' Analys Journal of Cardiovascular Development and Disease, 2021, 8, 120.	^{;is} 0.8	9
39	The importance of adherence and persistence with oral anticoagulation treatment in patients with atrial fibrillation. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f81-f83.	1.4	8
40	How did COVID-19 affect medical and cardiology journals? A pandemic in literature. Journal of Cardiovascular Medicine, 2021, 22, 840-847.	0.6	8
41	The challenge to improve knowledge on the interplay between subclinical atrial fibrillation, atrial cardiomyopathy, and atrial remodeling. Journal of Cardiovascular Electrophysiology, 2021, 32, 1364-1366.	0.8	7
42	Anticoagulation to prevent ischaemic stroke in patients with atrial fibrillation: a complex scenario including underdiagnosis, undertreatment, or underdosing of oral anticoagulants. European Heart Journal Quality of Care & Clinical Outcomes, 2020, 6, 95-97.	1.8	6
43	Impact of body mass index on the outcome of elderly patients treated with transcatheter aortic valve implantation. Internal and Emergency Medicine, 2022, 17, 369-376.	1.0	6
44	Impact of COVID-19 in emergency medicine literature: a bibliometric analysis. Internal and Emergency Medicine, 2022, 17, 1229-1233.	1.0	6
45	Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESCâ€EHRA EURObservational research programme in atrial fibrillation general longâ€ŧerm registry. European Journal of Clinical Investigation, 2022, 52, e13773.	1.7	6
46	Infective endocarditis in patients with cardiac implantable electronic devices: Impact of comorbidities on outcome. European Journal of Internal Medicine, 2019, 66, e9-e10.	1.0	5
47	The 12-lead ECC: a continuous reference for the cardiologist. Journal of Cardiovascular Medicine, 2019, 20, 459-463.	0.6	5
48	Tailored oral anticoagulant prescription in patients with atrial fibrillation: Use and misuse of clinical risk prediction scores. European Journal of Preventive Cardiology, 2020, 27, 726-728.	0.8	5
49	Antithrombotic treatment in atrial fibrillation patients undergoing percutaneous coronary interventions: focus on stent thrombosis. Expert Review of Cardiovascular Therapy, 2020, 18, 587-600.	0.6	5
50	Digital literacy as a potential barrier to implementation of cardiology tele-visits after COVID-19 pandemic: the INFO-COVID survey. Journal of Geriatric Cardiology, 2021, 18, 739-747.	0.2	5
51	Cardioversion of recent-onset atrial fibrillation: current evidence, practical considerations, and controversies in a complex clinical scenario. Kardiologia Polska, 2020, 78, 1088-1098.	0.3	5
52	Kidney Function According to Different Equations in Patients Admitted to a Cardiology Unit and Impact on Outcome. Journal of Clinical Medicine, 2022, 11, 891.	1.0	5
53	Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry. European Journal of Internal Medicine, 2022, 99, 45-56.	1.0	5
54	The search for a gold standard to clinically diagnose and monitor atrial cardiomyopathy. European Journal of Internal Medicine, 2022, 101, 34-36.	1.0	5

MARCO VITOLO

#	Article	IF	CITATIONS
55	Driving restriction in patients with cardiac implantable electronic devices: an overview of worldwide regulations. Expert Review of Medical Devices, 2020, 17, 297-308.	1.4	4
56	Biomarkers in atrial fibrillation: a constant search for simplicity, practicality, and cost-effectiveness. Kardiologia Polska, 2021, 79, 243-245.	0.3	4
57	Red blood cell distribution width in patients undergoing transcatheter aortic valve implantation: Implications for outcomes. International Journal of Clinical Practice, 2021, 75, e14153.	0.8	4
58	Burden of disease and costs of infections associated with cardiac implantable electronic devices. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 7-16.	0.7	4
59	Atrial high rate episodes as a marker of atrial cardiomyopathy: In the quest of the Holy Grail. Author's reply. European Journal of Internal Medicine, 2022, 98, 115-116.	1.0	4
60	Dronedarone for the treatment of atrial fibrillation with concomitant heart failure and preserved or mildly reduced ejection fraction: closer to Ithaca after a long odyssey?. European Journal of Heart Failure, 2022, 24, 1102-1105.	2.9	4
61	Cardiomyopathy associated with longâ€ŧerm right ventricular pacing: an intriguing clinical issue. European Journal of Heart Failure, 2019, 21, 652-654.	2.9	3
62	Female sex and stroke in atrial fibrillation: an intriguing relationship. Internal and Emergency Medicine, 2020, 15, 175-179.	1.0	3
63	Clinical implications of assessing frailty in elderly patients treated with permanent cardiac pacing. Journal of Cardiovascular Medicine, 2022, 23, 87-90.	0.6	3
64	Impact of anthropometric factors on outcomes in atrial fibrillation patients: analysis on 10 220 patients from the European Society of Cardiology (ESC)-European Heart Rhythm Association (EHRA) EurObservational Research Programme on Atrial Fibrillation (EORP-AF) general long-term registry. European Journal of Preventive Cardiology, 0, , .	0.8	3
65	Cardiac resynchronization therapy: need to synchronize patients and device longevities with comorbidities. Europace, 2019, 21, 683-685.	0.7	2
66	Why Is Atrial Fibrillation So Frequent in Hypertensive Patients?. American Journal of Hypertension, 2020, 33, 1067-1070.	1.0	2
67	From meta-analysis to the individual patient with atrial fibrillation and coronary artery disease: the complexity of antithrombotic treatment in real-world clinical practice and the need for a tailored approach. European Journal of Internal Medicine, 2020, 77, 27-29.	1.0	2
68	Cardiac resynchronization therapy: variations across Europe in implant rates and types of implanted devices. Journal of Cardiovascular Medicine, 2021, 22, 90-93.	0.6	2
69	Clinical Profile, Arrhythmias, and Adverse Cardiac Outcomes in Emery–Dreifuss Muscular Dystrophies: A Systematic Review of the Literature. Biology, 2022, 11, 530.	1.3	2
70	Chronic Kidney Disease with Mild and Mild to Moderate Reduction in Renal Function and Long-Term Recurrences of Atrial Fibrillation after Pulmonary Vein Cryoballoon Ablation. Journal of Cardiovascular Development and Disease, 2022, 9, 126.	0.8	2
71	Grey zones in the practice of permanent cardiac pacing: The case of preventive pacing for improving rhythm control in atrial fibrillation. International Journal of Clinical Practice, 2021, 75, e13728.	0.8	1
72	Permanent Atrial Fibrillation as the Terminal Stage of a Chronic Disease: Palliative Care Needs to be Considered in Selected Patients with Markedly Impaired Quality of Life. Cardiology, 2021, 146, 397-399.	0.6	1

#	Article	IF	CITATIONS
73	Infection of Cardiac Implantable Electrical Devices: An Emerging Epidemiological Issue. , 2020, , 1-16.		0
74	444 Epidemiology of subclinical atrial fibrillation in patients with cardiac implantable electronic devices: a systematic review and meta-regression. European Heart Journal Supplements, 2021, 23, .	0.0	0
75	Implantable cardioverterâ€defibrillators for primary prevention of sudden cardiac death: what are the barriers to implementation in the â€real world'?. European Journal of Heart Failure, 2022, 24, 1223-1226.	2.9	0